Prestige Biopharma eyes at least 1.8t won valuation in Korean IPO
Biotech firm also plans to expand its headcount to about 300 in next five years
Add BT as a preferred source
Singapore
SINGAPORE-BASED Prestige Biopharma expects an implied market capitalisation of between 1.8 trillion won and 1.93 trillion won (S$2.2 billion to S$2.3 billion) in its upcoming initial public offering (IPO) on the Korea Exchange (KRX), the company told The Business Times.
As it looks to list early this year, the biotech firm also plans to expand its headcount from the current 70 to about 300 staff, possibly in the next five years, its chief executive Lisa Park told BT.
TRENDING NOW
Jaecoo 8 review: a three-row SUV that excels at one thing
Johor property old hand KSL readies family handover amid market boom
Battle for Asia’s ultra-rich: ‘Singapore can’t afford to keep losing clients to Dubai, Hong Kong’
Yeo’s, Tiger Beer and now Gardenia – flight of food manufacturing from Singapore might be just as planned
